No Data
Brother Enterprises Holding (002562.SZ): Lacosamide injection has been approved for market launch.
On March 3, Gelonghui reported that Brother Enterprises Holding (002562.SZ) announced that its wholly-owned subsidiary, Zhejiang Brother Pharmaceutical Co., Ltd. (referred to as 'Brother Pharmaceutical'), recently received the 'Drug Registration Certificate' (Certificate No.: 2025S00546) issued by the National Medical Products Administration for lacosamide injection. Lacosamide injection is suitable for adjunctive treatment of partial-onset seizures in patients aged 4 years and older with epilepsy. Lacosamide is a third-generation antiepileptic drug that controls sodium channel slow inactivation, reducing neuronal excitability by regulating sodium ion channel activity, with good tolerance and high safety characteristics. According to the Mininetwork data.
Brother Enterprises Holding (002562.SZ): Currently, the prices of chromium salt products are relatively stable.
On February 17, Gelonghui reported that Brother Enterprises Holding (002562.SZ) stated on the investor interaction platform that the prices of the company's chromium salt products are currently relatively stable.
Brother Technology: Brother Technology 2024 Annual Results Forecast
Brother Enterprises' Subsidiary Gets Nod to Market Iopamidol
Brother Enterprises Holding (002562.SZ): Brother Pharmaceuticals received the approval notification for the market application of the Active Pharmaceutical Ingredient Iopamidol.
On January 16, Gelonghui reported that Brother Enterprises Holding (002562.SZ) announced that its wholly-owned subsidiary Jiangxi Brother Pharmaceutical Co., Ltd. (referred to as "Brother Pharmaceutical") recently received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration. The approval of the Active Pharmaceutical Ingredient product iodipamide indicates that this Active Pharmaceutical Ingredient has met the relevant technical standards for review of Active Pharmaceutical Ingredients in the country. After complying with the requirements of Good Manufacturing Practice for Pharmaceuticals, it can be produced and sold in the domestic market, positively impacting the capacity release of the company's iodinated contrast agent Active Pharmaceutical Ingredient project and further market expansion.
Individual Investors Among Brother Enterprises Holding Co.,Ltd.'s (SZSE:002562) Largest Stockholders and Were Hit After Last Week's 9.7% Price Drop
Returns On Capital At Brother Enterprises HoldingLtd (SZSE:002562) Paint A Concerning Picture
